Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Severe cognitive impairment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: Severe cognitive impairment. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-001850-13 Sponsor Protocol Number: GLP-1/MCI Start Date*: 2015-09-11
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia?
    Medical condition: Moderate cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003188-13 Sponsor Protocol Number: CONIVAD Start Date*: 2016-09-23
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: Pilot study on the association choline alphoscerate-nimodipine in patients with subcortical vascular cognitive impairment
    Medical condition: Subcortical vascular cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009843 Cognitive deterioration LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000222-19 Sponsor Protocol Number: H2020-PHC-18-2015-667224 Start Date*: 2017-08-02
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiori...
    Medical condition: Perinatal Asphyxia, hypoxic-ischemic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    20.0 10029205 - Nervous system disorders 10014633 Encephalopathy neonatal PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) EE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) PT (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005442-37 Sponsor Protocol Number: CT200601 Start Date*: 2007-01-08
    Sponsor Name:University Medical Center St Radboud, department of neurology
    Full Title: PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance...
    Medical condition: isolated growth hormone deficiency after traumatic brain injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003705-17 Sponsor Protocol Number: LUMC-NECH-201801-ACA Start Date*: 2019-03-22
    Sponsor Name:LUMC
    Full Title: Prevention of neuropsychiatric adverse effects caused by dexamethasone: translational insights from a placebo-controlled trial with hydrocortisone.
    Medical condition: Neuropsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005723-33 Sponsor Protocol Number: amantadineSCEDI. Start Date*: 2015-03-27
    Sponsor Name:GGZ Oost Brabant
    Full Title: Efficacy of amantadine on behavioural and emotional problems and impairment of executive functioning due to acquired brain injury to the frontal lobes: a series of single case experimental design s...
    Medical condition: behavioural and emotional problems and impairment of executive functioning due to acquired brain injury to the frontal lobes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000394-60 Sponsor Protocol Number: ACR16C007 Start Date*: 2004-06-30
    Sponsor Name:A. Carlsson Research AB
    Full Title: A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease
    Medical condition: ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CN...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002582-37 Sponsor Protocol Number: CS001/2005 Start Date*: 2006-01-13
    Sponsor Name:Allergie-Centrum-Charité Universitätsmedizin Berlin
    Full Title: Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients
    Medical condition: Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005633-33 Sponsor Protocol Number: 202000842 Start Date*: 2021-06-02
    Sponsor Name:University Medical Center Groningen
    Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
    Medical condition: A depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003287-18 Sponsor Protocol Number: PET-FRAX-001 Start Date*: 2008-09-17
    Sponsor Name:University Antwerp [...]
    1. University Antwerp
    2. University Hospital Leuven gasthuisberg
    Full Title: Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil.
    Medical condition: Fragile X syndrome is the most common form of inherited mental retardation with a prevalence of 1/4000 males and 1/6000 females. Patients are characterized by a mild to severe form of cognitive imp...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005784-24 Sponsor Protocol Number: MEIXO-VALV-001 Start Date*: 2012-06-14
    Sponsor Name:Andres Iñiguez Romo
    Full Title: Dual antiplatelet therapy versus oral anticoagulation for a short time to prevent cerebral embolism after percutaneous aortic valve implantation. Multicenter randomized clinical trial.
    Medical condition: Evaluate the efficacy of dual antiplatelet therapy versus oral anticoagulation for primary prevention of cerebral thromboembolism at three months after percutaneous aortic valve implantation (TAVI).
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003825-27 Sponsor Protocol Number: 263CS201 Start Date*: 2020-06-02
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-004172-30 Sponsor Protocol Number: PREPARE Start Date*: 2021-10-13
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe...
    Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006203-36 Sponsor Protocol Number: NL21082.000.08 Start Date*: 2007-05-23
    Sponsor Name:Academic Medical Centre (AMC)
    Full Title: Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome
    Medical condition: Dementia in velocardiofacial syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012267 Dementia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002282-35 Sponsor Protocol Number: rh-NGF Start Date*: 2020-05-13
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug
    Medical condition: Persistent unresponsive wakefulness syndrome (UWS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10049615 Late effects of head trauma LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000730-42 Sponsor Protocol Number: ARG-E07 Start Date*: 2009-01-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrom...
    Medical condition: Heparin induced thrombocytopenia (HIT) Type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048672 Heparin-induced thrombocytopenia type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000070-29 Sponsor Protocol Number: 74668 Start Date*: 2022-09-15
    Sponsor Name:VU University Medical Center
    Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
    Medical condition: Pelizaeus-Merzbacher disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002843-11 Sponsor Protocol Number: BAN2401-G000-201 Start Date*: 2013-04-26
    Sponsor Name:Eisai Limited
    Full Title: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With E...
    Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2005-001281-13 Sponsor Protocol Number: KS-2004-06-SET Start Date*: 2005-11-15
    Sponsor Name:DSC Services, s.r.o.
    Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)
    Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001356-20 Sponsor Protocol Number: 0602001 Start Date*: 2006-06-05
    Sponsor Name:Reckitt Benckiser (UK) Limited
    Full Title: A preliminary single dose, three-way, double-blind, placebo-controlled crossover study of intravenous buprenorphine/naloxone in the treatment of neuropathic pain of diabetic neuropathy origin.
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:49:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA